A TRPV2 interactome-based signature for prognosis in glioblastoma patients by Doñate-Macián, Pau et al.
Oncotarget18400www.oncotarget.com
A TRPV2 interactome-based signature for prognosis in glioblastoma 
patients 
Pau Doñate-Macián1,*, Antonio Gómez2,3,*, Irene R. Dégano4,5 and Alex Perálvarez-
Marín1
1Unitat de Biofísica, Departament de Bioquímica i de Biologia Molecular, Facultat de Medicina, Universitat Autònoma de 
Barcelona, Bellaterra, Catalonia, Spain
2Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain
3Universitat Pompeu Fabra, (UPF), Barcelona, Catalonia, Spain
4CIBER Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
5REGICOR Study Group, Cardiovascular Epidemiology and Genetics Group, IMIM (Hospital Del Mar Medical Research 
Institute), Barcelona, Catalonia, Spain
*These authors contributed equally to this work
Correspondence to: Alex Perálvarez-Marín, email: alex.peralvarez@uab.cat
Keywords: TRPV2; proteomics; glioblastoma multiforme; gene-disease associations; gene signature
Received: July 02, 2017    Accepted: March 01, 2018    Published: April 06, 2018
Copyright: Doñate-Macián et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 
License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author 
and source are credited.
ABSTRACT
Proteomics aids to the discovery and expansion of protein-protein interaction 
networks, which are key to understand molecular mechanisms in physiology and 
physiopathology, but also to infer protein function in a guilt-by-association fashion. 
In this study we use a systematic protein-protein interaction membrane yeast two-
hybrid method to expand the interactome of TRPV2, a cation channel related to nervous 
system development. After validation of the interactome in silico, we define a TRPV2-
interactome signature combining proteomics with the available physio-pathological 
data in Disgenet to find interactome-disease associations, highlighting nervous 
system disorders and neoplasms. The TRPV2-interactome signature against available 
experimental data is capable of discriminating overall risk in glioblastoma multiforme 
prognosis, progression, recurrence, and chemotherapy resistance. Beyond the impact on 
glioblastoma physiopathology, this study shows that combining systematic proteomics 
with in silico methods and available experimental data is key to open new perspectives 
to define novel biomarkers for diagnosis, prognosis and therapeutics in disease.
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INTRODUCTION
Among transient receptor potential (TRP) channels, 
the TRP vanilloid 2 (TRPV2) cation channel is a thermal, 
mechanical, and lipid sensor related to a wide span 
of physiological roles such as thermogenesis, cardiac 
structure, neuromuscular development and function, etc. 
[1–4]. The lack of information on TRPV2 regulation, 
and about endogenous or pharmacological modulation, 
has hindered the association of TRPV2 to key human 
physiopathology processes. To assess TRPV2 function, 
several attempts have focused on TRPV2 protein-protein 
interactions (PPI). Some of the interactors for TRPV2 have 
been inferred through in silico methods, using sequence 
conservation of specific motifs in the TRPV1-4 subgroup 
[5]. Classical PPI studies have identified TRPV2 partners, 
such as RGA or NGF-1 [6, 7].  
PPI screenings rely in the understanding of a 
protein-of-interest physiological function using a guilt-
by-association approach [8]. These PPI have to be 
further validated in an appropriate physiological system, 
becoming the time-limiting step for the discovery of 
protein-function or protein-disease associations. The 
molecular identity of the interactors is expected to indicate 
potential useful mechanisms. In a guilt-by-association 
fashion the TRPV2-NGF-1 interaction would suggest 
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the role of TRPV2 in neural development, confirming 
previous results relating TRPV2 to central nervous system 
(CNS) physiology [7, 9]. 
In silico approaches have taken advantage of gene 
and protein annotation to computationally refine the 
number of valid PPI [10, 11]. Availability of experimental 
data in public databases opens new perspectives for cross-
validation of PPI, to assess the robustness of interactomes 
derived from systematic high-throughput experimental 
screenings, to associate protein to diseases and to build 
gene/protein signatures for disease therapeutics, diagnosis 
and /or prognosis [12].
In this study we propose a guilt-by-association 
experimental approach to identify TRPV2’s PPI aiming 
to answer physiologically relevant questions for this 
ubiquitous, but elusive ion channel. Using unsupervised 
in silico approaches we assessed the robustness of the 
interactome, and then we cross-validated the TRPV2 
interactome with disease association databases to define 
physiopathological implications. Finally, using a patient 
cohort, we defined a significant TRPV2 interactome-based 
signature for the prognosis of an important brain disease, 
such as glioblastoma multiforme (GBM) and we validated 
the defined signature in two independent cohorts.
RESULTS
TRPV2 interactome
Figure 1A shows the co-immunoprecipitation of 
TRPV2 with snapin and synaptotagmin-IX in HEK293T 
cells, using TRPV1 as positive control for the interaction 
[13]. To define the TRPV2 interactome, we used a split-
ubiquitin-based membrane yeast two-hybrid (MYTH) 
assay [14, 15] to screen a human brain cDNA library, where 
we identified 20 positive TRPV2 interactors, depicted 
in Figure 1B and Supplementary Table 1. The positive 
interactors for human TRPV2 that had highest growth 
over selective media and strongest blue color intensity in 
the presence of X-Gal were: ABR, ARL15, NTM, Opalin, 
SACM1L and ST18 (Figure 1B). The transformants that 
showed the dimmest blue color intensity were: PIP4K2B, 
INPP5F, SDC3 and ALDH1A3. These interactors were able 
to grow under selective conditions, although they did not 
turn intensely blue in presence of X-Gal (Figure 1B).
Bioinformatics validation of TRPV2 interactome 
TRPV2 and its interactors (MYTH hits, snapin, 
and synaptotagmin-IX) define a putative protein-protein 
interaction network of 23 proteins (blue nodes in Figure 
2A). We expanded the network with the 20-closest genes 
of the 23 proteins of interest (grey nodes in Figure 2A). The 
gene-enriched TRPV2 network showed significant higher 
interconnectivity than 15 randomly generated networks, 
enriched using 20, 100, or 200 of the network closest-genes 
(Figure 2B). Regarding the gene ontology terms (GO-
terms) used, 4 of them; co-expression, co-localization, 
genetic and physical interactions, and shared protein-
domains terms, are capable of distinguishing the TRPV2 
interactome from randomly generated interactomes (Figure 
2C and Supplementary Table 2). We browsed in Disgenet 
for interactome-disease associations [16], rather than unique 
gene-disease associations, to evaluate the type of tissue-
specific disease where our TRPV2-interactome presented a 
higher association. Neoplasms and nervous system diseases 
were the top disease classes represented in Disgenet for all 
the interactome (except for Snapin and Opalin that were 
not present in any of the gene-disease databases available 
for Disgenet, Figure 3A). The neoplasms with higher gene-
disease associations were metastatic neoplasms and breast-
related neoplasms (Supplementary Figure 2). Since the 
MYTH was performed using a human brain cDNA library, 
we intersected both neoplasms and CNS diseases to identify 
the brain neoplasms more associated with our TRPV2 
interactome (Figure 3B). The TRPV2 interactome showed 
a high association with early glia-related neoplasms, 
especially glioma/glioblastoma, being ABR, FGF1, 
KCNJ10, PEBP1, PLP1, SDC3, and TRPV2, the genes 
associated to these brain neoplasms. This subset of proteins 
defined an initial 7-gene signature for GBM, consisting of 
genes that have been previously associated to GBM or early 
stage gliomas, as found in Disgenet (Figure 3B). 
Evaluation of TRPV2 interactome-based 
signature for prognosis in Glioblastoma patients
The TRPV2 interactome-based signature (all 23 
genes) was evaluated in 87 glioblastoma patients from the 
Chinese Glioma Genome Atlas (CGGA) dataset. Survival 
of the groups is shown in Figure 4A. Patients with high 
TRPV2 interactome expression (high-risk scores) had 
shorter median OS than patients with low expression (low-
risk scores) in GBM (multivariate Cox analysis points to 
risk score as an independent prognostic factor, p < 0.001 
log-rank test, Figure 4A).  Using the median risk score as 
the cutoff value, the patients were successfully clustered 
into high- and low-risk groups (Figure 4B). Based on the 
developed signature, low-risk patients had a lower risk 
of death compared to high-risk patients in unadjusted 
analyses (HR = 0.09, 95% CI, 0.05–0.19) (Figure 4C). No 
significant differences were found by gender while risk of 
death was borderline higher in older patients (HR = 1.74, 
95% CI, 0.99–3.05).
Validation of the prognostic value of TRPV2 
interactome-based signature in additional 
Glioblastoma datasets
The validation cohort included 71 GBM patients. 
Consistent with the results from the CGGA cohort, the 
signature successfully discriminated patients with poor 
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prognosis (high-risk) from those with a better prognosis 
(low-risk In the REMBRANDT dataset, Figure 4D, 4E). 
Multivariate Cox analysis indicated that the risk score was an 
independent prognostic factor of OS (p < 0.05 log-rank test) 
(Figure 4D). The trend to a higher risk of death observed 
in CGGA older patients was also found significant in 
REMBRANDT (HR = 2.42, 95% CI, 1.42–4.1, Figure 4F). 
GBM patients, as other type of neoplasm, show 
altered DNA repair pathways leading to chemotherapy 
resistance. Temozolomide sensitivity has been related to 
overexpression of O6-methylguanine methyltransferase 
(MGMT) and/or lack of DNA repair [17]. Using the 
REMBRANDT cohort, we could study the relationship 
between MGMT, base excision repair (BER) genes, and 
TRPV2, to infer whether our TRPV2-interactome signature 
could be of use to assess chemotherapy resistance in GBM 
patients. The OS in this subset indicates that the risk score is 
an independent prognostic factor (p = 0.00011 log-rank test, 
Supplementary Figure 3A), and the low risk group shows 
overexpression of MGMT and TRPV2 and underexpression 
of BER genes (Supplementary Figure 3B).
We further tested the robustness of the TRPV2-
interactome signature using another independent cohort 
with drug resistance (Temozolomide), progression and 
Figure 1: TRPV2 Interactome. (A) Validation by coimmunoprecipitation of the physical interaction between TRPV2 (GFP-HIS 
tagged) and synaptotagmin-IX and snapin (Myc tagged) in HEK293 cells. An illustrative cartoon depicts TRPV2 domain organization 
and the position of the tags. (B) TRPV2 interactors discovered in the MYTH assay. The TRPV2 (Cub tagged) and prey (NubG tagged 
on c terminal, x-NubG) interactions were grown in 10 mM 3AT SD-LEU-TRP-HIS or 5 mM 3AT SD-LEU-TRP-HIS selective plates 
(Cub-TRPV2 and, TRPV2-Cub respectively) and produced the characteristic blue color from X-Gal metabolism due to expression of 
B-galactosidase reporter. Colony growth and blue color intensity indicates the strenght of the interaction. As control, we include APP-Cub 
(amyloid precursor protein), and free NubG as bait and prey plasmids, respectively.
Figure 2: TRPV2 interactome gene enrichment analysis. (A) Gene enrichment using the 20 closest related genes. The network 
generated connects TRPV2 MYTH plus CoIP interactors (blue dots) and 20 closest related genes (grey dots) according with the following 
GO-terms: gene co-expression (purple lines); co-localization (blue lines); genetic interactions (green lines); physical interactions (red 
lines) and shared domains (brown lines). (B) Network interconnectivity measured as the ratio of edges:nodes within the network. TRPV2 
interactome from MYTH plus CoIP was compared with randomly generated networks (n = 16). The analysis was performed using a gene 
enrichment of 20, 100 or 200 closest related genes (GE 20, GE100 and GE200 respectively). (C) The nature of the network interconnectivity 
was assessed for TRPV2 interactome and randomly generated networks. The percentage of each type of connection over total connections 
within the network was represented. ***indicates p-values < 0.001 between compared groups.
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recurrence information, the Cancer Genome Atlas (TCGA) 
GBM data of 285 patients. Kaplan-Meier plots showed 
significant differences in OS between the low and high-
risk groups (HR = 0.49, 95% CI, 0.37–0.65; Figure 5A). 
Moreover, significant differences are shown regarding 
age, and Temozolomide resistance, but also for GBM 
progression and recurrence (Figure 5B). 
Functional annotation of the interactome 
signature
In order to find out the functional basis of the 
notable difference in prognosis, we also performed 
differential expression analysis on high- and low-
risk patients in the three datasets. Those genes with 
false discovery rate (FDR) < 0.05 were considered to 
be differentially expressed between the two groups 
(Supplementary Table 3). The overlapped genes 
(Supplementary Table 4) were chosen for further analysis. 
Gene ontology (GO) enrichment analysis revealed that 
the associated genes, among those highly expressed in 
the high-risk group, were primarily associated with the 
nervous system development, neuron differentiation, 
regulation of cell morphogenesis, axon development, 
cell morphogenesis involved in neuron differentiation, 
and synaptic transmission and signaling (Supplementary 
Figure 4), agreeing with the bioinformatics validation of 
the interactome (see above).
DISCUSSION
In this study, we used a guilt-by-association discovery 
approach to unravel the role of TRPV2 and its PPI in 
CNS pathophysiology. The putative TRPV2 interactome 
consists of TRPV2 + 22 proteins derived from canonical 
immunoprecipitation studies and a systematic PPI screening 
among which ABR, ARL15, NTM, Opalin, SACM1L 
and ST18, seem to have the strongest interaction with 
TRPV2. The defined TRPV2 interactome showed higher 
interconnectivity than randomly generated networks 
and 4 GO terms allowed its differentiation from random 
interactomes. The most associated diseases with the TRPV2 
interactome were neoplasms and diseases from the nervous 
system, and ABR, FGF1, KNJ10, PEBP1, PLP1, SOC3, and 
TRPV2 were found to be associated with brain neoplasms. 
Expression of the TRPV2 interactome was significantly 
associated with less survival of glioblastoma patients in 
a derivation and 2 validation cohorts. In addition, high 
expression of the TRPV2 interactome showed a higher risk 
for older individuals and was associated with progression, 
recurrence, and drug resistance. 
Our study identified a set of 22 proteins as potential 
interactors of TRPV2. The proteins present in our 
interactome include transport proteins (TRPV2, KCNJ10, 
CACNG3, SLC44A2), catalytic proteins (ALDH1A3, 
INPP5F, PIP4K2B), trafficking proteins (ARF1, ARL15, 
ABR, SYT-9, SNAPIN), signaling molecules (FGF1, 
ST18, SHISA6, CDH6, SDC3), myelin components 
(PLP1, Opalin, NTM), lipid metabolism proteins 
(SACM1L, PEBP1, INPP5F, PIP4K2B), etc. From the 
identified proteins ABR, ARL15, NTM, Opalin, SACM1L 
and ST18, appear to have the strongest interaction with 
TRPV2. Using a gene-enrichment FDR approach, we 
showed that TRPV2 interactome interconnectivity was 
significantly larger than randomly generated interactomes. 
The higher interconnectivity relates to the robustness of 
the experimental set of interactors for TRPV2, indicating 
low or none contribution of false positive interactors to 
Figure 3: TRPV2 interactome-disease associations. (A) Single gene-disease associations derived from Disgenet. The red-line 
frame highlights the top-ranked gene-disease associations. (B) Gene-disease associations for CNS/brain neoplasms, according to the 2016 
WHO classification for CNS tumors [31] were plotted to show the unique genes previously associated to brain neoplasms.
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the TRPV2 network. Thus, if the interactome is robust 
as the identified TRPV2 interactome, it should behave as 
a functional unit in physiological or physiopathological 
conditions. The gene-enrichment analyses highlighted 
specific GO-terms, such as protein co-localization, protein 
shared domains, and protein physical interactions. These 
GO-terms point to molecular mechanisms, rather than 
single gene-functions in line with the different functions of 
the interactome proteins. This approach does not validate 
the physical interactions within TRPV2 interactome 
per se, but argues for the robustness of the interactome 
and indicates a high degree of relationship between the 
proteins and/or their biochemical function, similarly to the 
scheme followed by de novo and in silico PPI predictors 
[10, 18]. Our in silico validation does not prevent the 
experimental validation, but serves as a tool to rank the 
interactors by specific GO-terms of interest and highlight 
the robustness of the interactions.
Assuming the TRPV2 interactome as a whole, instead 
of a sum of proteins, we have used it as input seed to obtain 
interactome-disease associations in Disgenet. To the best 
of our knowledge, this is the first time that this approach 
has been used. This analysis identified neoplasms and 
nervous system diseases as the most associated diseases 
with the TRPV2 interactome, and highlighted a set of 
genes previously associated to brain neoplasms, such as: 
ABR, FGF1, KCNJ10, PEBP1, PLP1, SDC3 and TRPV2. 
TRPV2 is overexpressed in GBM [19] and it has been 
shown that its activation by cannabidiol sensitizes GBM 
cells to chemotherapeutics and also inhibits proliferation of 
Glioblastoma stem-cell like cells [20, 21].
GBM is the most common primary brain neoplasm 
and one of the worst in terms of treatment and prognosis, 
with an incidence of 3 cases per 100,000 people and a 
median survival of 12 months [22, 23]. Many efforts are 
directed towards the understanding of the malignancy of 
glioblastoma to find therapeutic and diagnostic tools to 
improve its prognosis. Gene-based signatures, opposite 
to single gene expression, have been widely used to 
understand neoplasms [12, 24]. A top-down supervised 
study based on the expression levels of ion channels in 
GBM identified a three-gene signature (KCNN4, KCNB1 
Figure 4: TRPV2 interactome-based glioblastoma signature using the CGGA database for building the signature and 
the REMBRANDT cohort for the validation of the signature prognostic power. (A, D) Survival plots for low-(blue) and high-
risk (red) patients in the CGGA database and REMBRANDT cohort, respectively. (B, E) Boxplots showing the difference in survival days 
between high- (red) and low-risk (blue) scores for CGGA database and REMBRANDT cohort, respectively. (C, F) Forest plots showing 
hazard ratios with 95% confidence intervals (CI) for CGGA database and REMBRANDT cohort, respectively. The variables used are risk, 
age, and gender.
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and KCNJ10) significantly associated with OS of GBM 
[25]. Our main result is a proteomics interactome-based 
signature for GBM prognosis derived in a GBM patient 
cohort and validated in 2 independent cohorts. The 
interactome-based signature significantly discriminates 
among high- and low-risk GBM in terms of OS time, 
but also in terms of GBM progression, recurrence, and 
Temozolomide resistance.  The results of the validation 
cohorts demonstrate the robustness of the signature to 
identify patients at high-risk of short survival and disease 
recurrence. Our results also suggest a benefit of adjuvant 
therapy for the TRPV2-interactome signature. The 
identified TRPV2-interactome-based signature represents 
a new set of potential biomarkers not only for the study 
of GBM, but for prognosis and therapeutics of one of the 
most malignant neoplasms.  
In conclusion, we have identified a set of TRPV2 
interactors using biochemical and computational 
analyses. This TRPV2 interactome is robust and it is 
particularly associated with neoplasms and diseases 
of the nervous system. Seven of these interactors have 
been associated with brain neoplasms in previous 
studies. Analyses in 3 different cohorts have shown that 
the identified TRPV2 signature is able to discriminate 
between glioblastoma patients at low- and high-risk in 
terms of survival. The TRPV2 signature is also associated 
with glioblastoma patient age, disease progression, 
recurrence, and drug resistance. Our results provide a 
protein signature that could be useful for GBM prognosis 
and treatment. Due to the potential implications of our 
work larger studies are needed to confirm the observed 
associations.  
MATERIALS AND METHODS
DNA plasmids and cell culture and transfection
cDNA sequences for rat TRPV1 and TRPV2 cloned 
into a pCDNA3 vector and Myc-his tagged snapin and 
synaptotagmin-IX cloned in a pcDNA3 vector were 
transiently transfected in cultured HEK 293T cells as 
described in Doñate-Macián et al. [26]. HEK293 cells 
overexpressing the transfected constructs were harvested 
48 hours after transfection and proteins solubilized in lysis 
buffer (50 mM Tris-HCL pH 7.4, 150 mM NaCl, 2 mM 
EDTA, 1% Triton-X100, 5% glycerol, 1 mM benzamidine 
and EDTA-free protease inhibition cocktail, ROCHE).
PBT3-STE and pBT3-N yeast expression vectors 
were used in the MYTH assay to express human TRPV2 
as bait (tagged with the C-terminus of split-ubiquitin at the 
C- and N-terminus, respectively) and a cDNA library from 
human brain (Dualsystems Biotech P12227, tagged with 
the mutated N-terminus of split-ubiquitin NubG). pTSU-
APP (amyloid precursor protein), and pPR3-N were used 
as control bait and control prey plasmids, respectively. 
Human TRPV2 full length, tagged with an eGFP at the 
C-terminus was cloned into pBT3-N and pBT3-STE 
within SfiI sites to monitor cellular expression.
Immunoprecipitation
500 µg of total protein from the cell extracts were 
incubated overnight at 4° C with anti-c-Myc antibody 
(BD Pharmingen, 551101). 50 µL of Sepharose-G 
beads were added and incubated for 2 hours at 4° C. 
Figure 5: Validation of the prognostic power of the TRPV2 interactome-based glioblastoma signature in the TCGA 
cohort with chemotherapy and tumor progression information. (A) Survival plot in low-(blue) and high-risk (red) patients 
classified by the TRPV2 interactome. (B) Forest plots showing hazard ratios with 95% confidence intervals (CI) for the variables risk, age, 
gender, new event, and drug resistance.
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Immunoprecipitated complexes were denatured with SDS-
PAGE sample buffer (90° C for 5 min), separated by SDS-
PAGE and analyzed by immunoblotting as previously 
described [26] using as primary antibodies anti-GFP 
from Developmental Studies Hybridoma Bank (DHSB 
GFP-G1) 1:1000 dilution and c-Myc  (BD Pharmingen, 
551101) 1:1000 dilution. Secondary antibody (Santa Cruz, 
anti-mouse sc-2031) 1:3000 dilution was incubated 1 
hour at room temperature. Detection was carried out with 
Illumina Crescendo reagent (Millipore).
Membrane yeast two-hybrid assay
MYTH assay as described by Snider et al. [27] was 
used to identify potential interactors for TRPV2. MYTH 
assay was performed in the reporter strain NMY51 [MATa 
his3delta200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)4-
HIS3 ura3::(lexAop)8-lacZ (lexAop)8-ADE2 GAL4)] 
(Dualsystems Biotech, P01401-P01429). Western blot against 
LexA tag (SC-7544HRP, Santa Cruz Biotech) was used to 
confirm the correct expression of the generated baits. NMY51 
yeast cells expressing GFP tagged baits were visualized using 
a Leica TCS SP5 confocal microscope (Supplementary 
Figure 1). Transformation efficiency of the human brain 
cDNA library into NMY51 cells carrying the bait constructs 
was assessed by counting the number of colonies growing 
on non-selective plates (SD-LEU-TRP). Transformation 
efficiency was higher than 2 × 106 colony forming units. 
Positive transformations were plated into SD agar selective 
plates as follows:  LexA-VP16-Cub-TRPV2 (subsequently 
called Cub-TRPV2) was plated in 10 mM 3AT SD-LEU-
TRP-HIS and TRPV2-Cub-LexA-VP16 (subsequently 
called TRPV2-Cub) in 5 mM 3AT SD-LEU-TRP-HIS. 
After incubation at 30° C for 3–5 days, transformants were 
transferred to same stringency selective plates containing 
5-bromo-4-chloro-3-indolyl-β,d-galactopyranoside (X-Gal) 
to assess B-galactosidase reporter gene expression. Prey 
plasmids DNA were isolated and transformed into DH5α E. 
coli competent cells to be sequenced. Isolated prey plasmids 
in frame with NubG carrying a putative interaction partner 
were transformed again into NMY51 strain containing the 
original bait and plated into selective plates with X-gal to 
confirm the interaction. Refer to Supplementary Figure 1 for 
further experimental details.
Interactome robustness and interconnectivity: 
gene enrichment and network analysis
Genes determined by the MYTH assay including 
TRPV2 (21 hits) and the 2 Co-IP hits were used to 
construct a network in Cytoscape [28] with the Genemania 
algorithm [29]. The network was constructed using as 
template the Genemania Human genome and adding the 
20, 100 or 200 closest related genes (GE20, GE100 and 
GE200 respectively) based on the following GO terms: 
colocalization, co-expression, physical interactions and 
domain conservation. An equal number of random genes 
(23) from human genome were used to construct networks 
using the same Genemania GO-terms. A total of 16 random 
networks were generated by this approach. Nodes and 
edges within each network were quantified and the ratio 
edges:nodes was used as a measure of network connectivity. 
Disgenet analysis
The disgenet2r R package [30] was used to obtain 
the genes associated to neoplasms. A list of genes was 
created with the 23 interactors identified.  All genes 
except for Opalin and Snapin were identified in the 
Disgenet database [16]. Gene-disease associations were 
obtained with the disgenetGene function and extracted 
to a data frame. Gene-disease associations for neoplasms 
and CNS/brain neoplasms, according to the 2016 WHO 
classification for CNS tumors [31] were plotted to show 
the genes associated to each disease.
Data integration and signature development
All clinical and gene expression data were collected 
previously and were available from public databases. 
Three databases were used in the analysis: CGGA 
(http://www.cgga.org.cn), TCGA (http://cancergenome.
nih.gov), and Repository for Molecular Brain Neoplasia 
Data  REMBRANDT (E-GEOD-68848, http://www.ebi.
ac.uk/ arrayexpress/). Specifically, in this study, we used 
data from three platforms: Affymetrix HG-U133Plus2 
(REMBRANDT) Agilent Whole Human Genome Oligo 
Microarray in a 4*44 (CGGA), and RNAseq (TCGA). 
Raw data (CEL files) for REMBRANDT data set 
were processed with the statistical algorithm Robust 
Multiarray Average (gcRMA) with the affy package of 
R/Bioconductor [32, 33]. Microarray analysis of CGGA 
glioma samples was performed with the Agilent Whole 
Human Genome Array, according to the manufacturer’s 
instructions.  Both in REMBRANDT and CGGA 
datasets, average values of replicate spots for each 
gene were background subtracted, normalized, log2-
transformed, for further analysis. TCGA level 3 gene 
expression levels (RNAseq) were obtained from the 
TCGA Data Portal in March 2017, in order to compare 
to microarray data, this data was normalized and log2-
transformed as well.
87 patients with microarray and clinical data 
available from CGGA were used as the training dataset, 
and the TCGA and REMBRANDT patients with all 
required information (285 and 71, respectively) were used 
as the validation datasets.
The 23 proteins were applied as a signature to 
develop a risk score (RS) formula in glioblastoma patients 
from the CGGA dataset:
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i
n
i= =
∑ ⋅( )βι
1
expr_level
Where β corresponds to the regression coefficient 
from the univariate Cox analysis to weigh the respective 
gene expression level (expr_level). Patients were stratified 
into high- and low-risk by using the 50th percentile risk 
score as the cut-off. 
Genes which were associated with grade progression 
and significant prognostic value (p-value < 0.05) were 
used to developed a linear combination of the gene 
expression level (expr_level) weighted by the regression 
coefficient derived from the univariate Cox regression 
analysis (β). For the signature validation, the β obtained 
in the derivation dataset were used and patients were also 
stratified into high- and low-risk as described above.
Statistical analysis
All statistical analysis were performed using R 
Statistical Software (version 3.2.1; Foundation for Statistical 
Computing, Vienna, Austria) [34].
Network interconnectivity from randomly obtained 
networks was compared to the TRPV2 generated 
network and significant differences were evaluated using 
T-test. P-values of GO-terms were calculated with the 
hypergeometric test and corrected with the Benjamini & 
Hochberg FDR algorithm. 
Analysis of differentially expressed genes was 
performed using the limma package in R [35]. Briefly, linear 
models were used to assess gene differential expression in the 
TRPV2-interactome gene set for multifactor data available in 
the TCGA, CGGA, and REMBRANDT databases.
Uni- and multivariate survival analyses were carried 
out with the R package Survival [36, 37] by performing 
Kaplan–Meier analyses with the log-rank test after the 
proportional hazards assumption was verified. Kaplan-
Meier curves were calculated to obtain survival estimates 
and the log-rank test to examine the differences between 
groups. OS was calculated as the interval from the day of 
first surgery to death or the end of follow-up. Multivariate 
survival analyses (Cox proportional hazard model) were 
used to take into account the joint effect of different 
covariates in OS. The included covariates were drug 
resistance, tumor progression and recurrence, gender, and 
age. Forest plots showing the hazard ratios (including 95% 
confidence intervals) for all cohorts were produced using 
R [34].
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